“So we know that the FDA already told NP that ph
Post# of 148179
NP did not say the FDA told him the phase 3 will be small. He’s assuming a phase 3 trial will require a small number of patients because of Leronlimab’s safety profile and the already statistically significant data from the M2M trial.